NCT03841396 is a Phase 4 clinical trial of Sodium chloride in Injection Site Reaction, sponsored by Aspen Global Incorporated.

Who is sponsoring NCT03841396?

NCT03841396 is sponsored by Aspen Global Incorporated.

What drugs are being tested in NCT03841396?

Interventions in NCT03841396: Sodium chloride.

What condition does NCT03841396 study?

NCT03841396 studies Injection Site Reaction.

Is NCT03841396 still recruiting?

NCT03841396 is currently completed. Last updated 15 February 2019.

Last reviewed 2019-02-15 · How we verify

NCT03841396

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study Comparing the Local Tolerability of Two Subcutaneous Heparins in Healthy Volunteers.

Completed Phase 4 Last updated 15 February 2019

What this trial tests

Phase 4 trial testing Sodium chloride in Injection Site Reaction in 15 participants. Completed in 15 July 2016.

Timeline

2 June 2016

Primary endpoint
15 July 2016

15 July 2016

Quick facts

Lead sponsor	Aspen Global Incorporated
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	double
Primary purpose	other
Enrollment	15
Start date	2 June 2016
Primary completion	15 July 2016
Estimated completion	15 July 2016

Drugs / interventions tested

Sodium chloride (Sodium Chloride) — full drug profile →

Conditions studied

Injection Site Reaction — all drugs for Injection Site Reaction →

Sponsor

Aspen Global Incorporated

Who can join

Adults 18 to 55, any sex, with Injection Site Reaction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase IV, Randomised, Double-blind, Single-centre clinical trial in healthy male and female participants aged 18 to 55, that was designed to assess and compare the pain intensity at an injection site as well as the duration of pain following a single dose subcutaneous administration of two low molecular weight heparins (LMWH) respectively.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Sodium chloride

Trials testing the same drug.

NCT06872060 — The Effects of Glucagon on Renal Regional Blood Flow in Humans Measured by Magnetic Resonance. · NA · not yet recruiting
NCT06305182 — Metreleptin in Anorexia Nervosa · Phase 2 · recruiting
NCT05564130 — Bicarbonate for In-Hospital Cardiac Arrest · Phase 4 · active not recruiting
NCT06494007 — Role of IV Calcium to Prevent Diltiazem-related Hypotension · Phase 4 · completed
NCT05582798 — Bronchiectasis Alpha-1 Augmentation Trial- Modulating Airway Neutrophil Function · Phase 4 · completed

Other Aspen Global Incorporated trials

Trials by the same sponsor.

NCT03809481 — Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban · Phase 3 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03841396 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aspen Global Incorporated
Last refreshed: 15 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03841396.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing